病理类医疗服务定价规范整合：人工智能辅助诊断明确收费路径

Investment Rating - The report assigns an "Accumulate" rating to the medical device industry, indicating a positive outlook for investment opportunities [4]. Core Insights - The National Healthcare Security Administration (NHSA) issued the "Guidelines for the Project Establishment of Pathology Medical Service Pricing (Trial)," which is expected to standardize the artificial intelligence-assisted diagnosis market [2][4]. - The guidelines consolidate existing pricing projects into 28 items, with 3 additional charges and 2 expansion items, aiming to create a unified pricing standard across provinces [4]. - The inclusion of "AI-assisted diagnosis" as an expansion item in the pricing guidelines is anticipated to regulate the market and stimulate research and development in the industry [4]. Summary by Sections - Policy Implementation: The NHSA's guidelines are part of a broader initiative to reform medical service pricing, promoting a structured approach to pricing in pathology services [4]. - Pricing Structure: The guidelines specify that the pricing for pathology diagnosis includes costs associated with sample reception, interpretation, diagnosis, AI assistance, and report generation [4]. - Digital Transformation: The requirement for medical institutions to upload pathology reports and digital images is expected to drive the adoption of digital technologies and facilitate nationwide sharing of diagnostic results [4].